Fighting the oldest epidemic
We have helped raise +$20 billion to support the Global Fund to Fight AIDS, TB, and Malaria and we’re just getting started
ACTION’s advocacy around TB—the issue that brought the partnership together over a decade ago—includes drug-resistant forms of TB and TB-HIV coinfection. We also work to align with global advocacy on other diseases of poverty, such as malaria, HIV/AIDS, and emerging diseases.
ACTION supports numerous global campaigns, including: the Global Fund to Fight AIDS, Tuberculosis and Malaria; the Global Plan to End TB; the antimicrobial resistance agenda; and Universal Health Coverage.
Our Ending the Epidemics Programming
ACTION’s advocacy focuses on protecting and increasing resources and improving policies and accountability to accelerate progress in the fight against HIV, TB, and malaria, with particular focus on TB.
The Global Fund
Global Health R&D
ACTION is committed to programming that invests in and aims to end TB through prevention; active case finding and contact tracing; focusing on marginalized communities; development and circulation of new tools; and implementing TB services that provide results in varying epidemic and socioeconomic environments.
Efforts within the antimicrobial resistance agenda, especially related to drug-resistant TB are critical; AMR has been identified as a top ten public health threat to humanity.
The Global Fund is a partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics.
The organization mobilizes and invests more than US$4 billion a year to support programs run by local experts in more than 100 countries. As a partnership of governments, civil society, technical agencies, the private sector and people affected by the diseases, the Global Fund pools the world’s resources to invest strategically in programs to end AIDS, TB and malaria as epidemics.
Global Health R&D
COVID-19 has provoked an ongoing global health crisis that has had devastating health and economic consequences and exacerbated health and economic inequities. The world’s response to COVID-19 and how we define pandemic preparedness going forward underscores the need for a comprehensive global strategy that prioritizes rapid development of effective new health tools (vaccines, diagnostics, therapeutics, and more), and access to these tools, through increased investment in research and development and consistent and at-scale financing for equitable delivery of global health interventions.